The burden and extent of comorbid conditions in patients with erectile dysfunction

International Journal of Clinical Practice

Volumn 63, Issue 8, 2009, Pages 1205-1213

  Hackett, G ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DYSLIPIDEMIA; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; COST OF ILLNESS; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; OBESITY; PROSTATISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 67749118034     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02088.x     Document Type: Review

References (97)

1. Rhoden EL, Teloken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 2002 14 : 245 50.
2. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999 84 : 50 6.
3. Baldwin K, Ginsberg P, Harkaway RC. Under-reporting of erectile dysfunction among men with unrelated urologic conditions. Int J Impot Res 2003 15 : 87 9.
4. Blanker MH, Bohnen AM, Groeneveld FP et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001 49 : 436 42.
5. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology 2004 64 : 1196 201.
6. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004 171 : 2341 5.
7. Sullivan ME, Thompson CS, Dashwood MR et al. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res 1999 43 : 658 65.
8. Meuleman EJ. Prevalence of erectile dysfunction: need for treatment? Int J Impot Res 2002 14 (Suppl. 1 S22 8.
9. Rosen RC, Fisher WA, Eardley I et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004 20 : 607 17.
10. Kendirci M, Nowfar S, Hellstrom WJ. The impact of vascular risk factors on erectile function. Drugs Today (Barc) 2005 41 : 65 74.
11. Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 2001 55 : 614 8.
12. Matfin G, Jawa A, Fonseca VA. Erectile dysfunction: interrelationship with the metabolic syndrome. Curr Diab Rep 2005 5 : 64 9.
13. McCulloch DK, Young RJ, Prescott RJ et al. The natural history of impotence in diabetic men. Diabetologia 1984 26 : 437 40.
14. Haro JM, Beardsworth A, Casariego J et al. Treatment-seeking behavior of erectile dysfunction patients in Europe: results of the Erectile Dysfunction Observational Study. J Sex Med 2006 3 : 530 40.
15. Ponholzer A, Temml C, Obermayr R et al. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? Eur Urol 2005 48 : 512 8.
16. Thompson IM, Tangen CM, Goodman PJ et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005 294 : 2996 3002.
17. Sun P, Swindle R. Are men with erectile dysfunction more likely to have hypertension than men without erectile dysfunction? A naturalistic national cohort study J Urol 2005 174 : 244 8.
18. Gazzaruso C, Solerte SB, Pujia A et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease. J Am Coll Cardiol 2008 51 : 2040 4.
19. Ma RCW, So WY, Yang XL et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008 51 : 2045 50.
20. Böhm M, Baumhäkel M, Probstfield JL et al. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J 2007 154 : 94 101.
21. Mittawae B, El-Nashaar AR, Fouda A et al. Incidence of erectile dysfunction in 800 hypertensive patients: a multicenter Egyptian national study. Urology 2006 67 : 575 8.
22. Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003 2 : 29 34.
23. Hood S, Robertson I. Erectile dysfunction: a significant health need in patients with coronary heart disease. Scott Med J 2004 49 : 97 8.
24. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003 89 : 251 3.
25. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994 151 : 54 61.
26. Kloner R, Padma-Nathan H. Erectile dysfunction in patients with coronary artery disease. Int J Impot Res 2005 17 : 209 15.
27. Kirby M. Lipid management can reduce CHD in diabetes. Best Pract 2001 26 : 31 2.
28. Kaya C, Uslu Z, Karaman I. Is endothelial function impaired in erectile dysfunction patients? Int J Impot Res 2006 18 : 55 60.
29. Uslu N, Gorgulu S, Alper AT et al. Erectile dysfunction as a generalized vascular dysfunction. J Am Soc Echocardiogr 2006 19 : 341 6.
30. Foresta C, Caretta N, Lana A et al. Circulating endothelial progenitor cells in subjects with erectile dysfunction. Int J Impot Res 2005 17 : 288 90.
31. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001 166 : 569 74.
32. Hackett GI. Impotence - the most neglected complication of diabetes. Diabetes Res 1995 28 : 75 83.
33. Sairam K, Kulinskaya E, Boustead GB et al. Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int 2001 88 : 68 71.
34. Cho NH, Ahn CW, Park JY et al. Prevalence of erectile dysfunction in Korean men with type 2 diabetes mellitus. Diabet Med 2006 23 : 198 203.
35. Eardley I, Fisher W, Rosen RC et al. The multinational Men's Attitudes to Life Events and Sexuality study: the influence of diabetes on self-reported erectile function, attitudes and treatment-seeking patterns in men with erectile dysfunction. Int J Clin Pract 2007 61 : 1446 53.
36. Klein R, Klein BE, Lee KE et al. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 1996 19 : 135 41.
37. Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2005 2 : 785 92.
38. Fedele D, Bortolotti A, Coscelli C et al. Erectile dysfunction in type 1 and type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int J Epidemiol 2000 29 : 524 31.
39. Cummings MH, Riley A, Noone M et al. Medication Utilised by UK men With Erectile Dysfunction and Diabetes Mellitus: Analysis From the Erectile Dysfunction Observational Study (EDOS). Glasgow : Diabetes UK, 2005.
40. Kapoor D, Aldred H, Clark S et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes, correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007 30 : 911 7.
41. Shabsigh R, Katz M, Yan G et al. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiology 2005 96 (Suppl. 1 67 72.
42. NICE guidance 66 on Diabetes. Type 2 diabetes: the management of type 2 diabetes (update 2008. http://www.nice.org.uk/Guidance/cg66
43. Nikoobakht M, Nasseh H, Pourkasmaee M. The relationship between lipid profile and erectile dysfunction. Int J Impot Res 2005 17 : 523 6.
44. Kim SC. Hyperlipidemia and erectile dysfunction. Asian J Androl 2000 2 : 161 6.
45. Derby CA, Mohr BA, Goldstein I et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000 56 : 302 6.
46. Bacon CG, Mittleman MA, Kawachi I et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003 139 : 161 8.
47. Chung WS, Sohn JH, Park YY. Is obesity an underlying factor in erectile dysfunction? Eur Urol 1999 36 : 68 70.
48. Riedner CE, Rhoden EL, Ribeiro EP et al. Central obesity is an independent predictor of erectile dysfunction in older men. J Urol 2006 176 : 1519 23.
49. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999 19 : 972 8.
50. Esposito K, Giugliano F, Di Palo C et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004 291 : 2978 84.
51. Heidler S, Temml C, Broessner C et al. Is the metabolic syndrome an independent risk factor for erectile dysfunction? J Urol 2007 177 : 651 4.
52. Peng YS, Chiang CK, Hung KY et al. The association of higher depressive symptoms and sexual dysfunction in male haemodialysis patients. Nephrol Dial Transplant 2007 22 : 857 61.
53. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999 19 : 67 85.
54. Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001 62 (Suppl. 3 22 34.
55. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 1995 25 : 191 201.
56. Roose SP. Depression: links with ischemic heart disease and erectile dysfunction. J Clin Psychiatry 2003 64 (Suppl. 10 26 30.
57. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003 44 : 637 49.
58. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000 12 : 305 11.
59. Frankel SJ, Donovan JL, Peters TI et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998 51 : 677 85.
60. Braun MH, Sommer F, Haupt G et al. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey" Eur Urol 2003 44 : 588 94.
61. Mariappan P, Chong WL. Prevalence and correlations of lower urinary tract symptoms, erectile dysfunction and incontinence in men from a multiethnic Asian population: Results of a regional population-based survey and comparison with industrialized nations. BJU Int 2006 98 : 1264 8.
62. Kaplan SA, De Rose AF, Kirby RS et al. Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. BJU Int 2005 97 : 559 66.
63. Wong P, Lawrentschuk N, Bolton DM. Phosphodiesterase 5 inhibitors in the management of benign prostatic hypertrophy and erectile dysfunction; the best of both worlds. Curr Opin Urol 2009 19 : 7 12.
64. Koseoglu N, Koseoglu H, Ceylan E et al. Erectile dysfunction prevalence and sexual function status in patients with chronic obstructive pulmonary disease. J Urol 2005 174 : 249 52.
65. Fletcher EC, Martin RJ. Sexual dysfunction and erectile impotence in chronic obstructive pulmonary disease. Chest 1982 81 : 413 21.
66. Halcox JP, Nour KR, Zalos G et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002 40 : 1232 40.
67. Rosano GM, Aversa A, Vitale C et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005 47 : 214 20.
68. Vlachopoulos C, Tsekoura D, Alexopoulos N et al. Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. Am J Hypertens 2004 17 : 1040 4.
69. Buranakitjaroen P, Mangklabruks A, Leungwattanakij S et al. Efficacy and safety of sildenafil in Asian males with erectile dysfunction and cardiovascular risk. J Med Assoc Thai 2007 90 : 1100 8.
70. Gori T, Sicuro S, Dragoni S et al. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005 111 : 742 6.
71. Baumhaekel M, Scheffler P, Boehm M. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res 2005 69 : 178 9.
72. Caretta N, Palego P, Ferlin A et al. Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil. Eur Urol 2005 48 : 326 31.
73. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004 47 : 1914 23.
74. Hassanein M, Riley A, Noone M, Beardsworth A. Prevalence and Severity of Erectile Dysfunction (ED) in UK Patients with Diabetes Mellitus from the Erectile Dysfunction Observational Study (EDOS). Glasgow : Diabetes UK, 2005.
75. Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002 25 : 2159 64.
76. Goldstein I, Young JM, Fischer J et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003 26 : 777 83.
77. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999 281 : 421 6.
78. Ziegler D, Merfort F, van Ahlen H et al. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006 3 : 883 91.
79. Hatzichristou D, Gambla M, Rubio-Aurioles E et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008 25 : 138 46.
80. Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002 168 : 1332 6.
81. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998 338 : 1397 404.
82. Hellstrom WJ, Gittelman M, Karlin G et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002 23 : 763 71.
83. McVary K, Roehrborn C, Kaminetsky J et al. The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Program and abstracts of the 21st EAU Congress, Paris, France, 5-8 April 2006 (Abstract 696).
84. Sairam K, Kulinskaya E, McNicholas TA et al. Sildenafil influences lower urinary tract symptoms. BJU Int 2002 90 : 836 9.
85. Charan NB. Does sildenafil also improve breathing? Chest 2001 120 : 305 6.
86. Miner M, Gilderman L, Bailen J et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008 5 : 1455 67.
87. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004 172 : 658 63.
88. Seidman SN, Roose SP, Menza MA et al. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001 158 : 1623 30.
89. Rosen R, Montorsi F, Assalian P et al. Efficacy and tolerability of vardenafil in men with major depressive disorder and erectile dysfunction: the Depression Related Improvement with Vardenafil for Erectile Response (DRIVER) study. XIXth EAU Congress, Vienna, 24-27 March 2004.
90. Rosen R, Shabsigh R, Berber M et al. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006 163 : 79 87.
91. Goldstein I, Kim E, Steers WD et al. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med 2007 4 : 166 75.
92. NICE public health guidance 15. Reducing the rate of premature deaths from cardiovascular disease and other smoking-related diseases: finding and supporting those most at risk and improving access to services, 2008. http://www.nice.org.uk
93. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res 2003 15 : 63 71.
94. MacDonagh R, Ewings P, Porter T. The effect of erectile dysfunction on quality of life: psychometric testing of a new quality of life measure for patients with erectile dysfunction. J Urol 2002 167 : 212 7.
95. Fisher WA, Rosen RC, Mollen M et al. Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005 2 : 699 708. (Pubitemid 41742930)
96. Hackett G, Kell P, Ralph D et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008 5 : 1841 6.
97. Wespes E, Amar E, Hatzichristou DG et al. EAU guidelines on erectile. dysfunction. Eur Urol 2002 41 : 1 5.